KEYMAKER-U03
Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)
- NCT04626518 ↗
- Completed
- Merck Sharp & Dohme LLC
- Focused
We haven't built an HCP commentary report on KEYMAKER-U03 (pembrolizumab/quavonlimab; favezelimab/pembrolizumab; pembrolizumab plus MK-4830 in second-line metastatic renal cell carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on KEYMAKER-U03 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 2 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants With RCC (KEYMAKER-U03): Substudy 03B in Second-Line Metastatic Participants
- Phase
- Phase 1/Phase 2
- Status
- Completed
- Conditions
- Carcinoma, Renal Cell
- Interventions
- Pembrolizumab; MK-4830; Belzutifan; Lenvatinib; Pembrolizumab/Quavonlimab; Favezelimab/Pembrolizumab
- Arms
- Coformulation Pembrolizumab/Quavonlimab · Experimental
- Coformulation Favezelimab/Pembrolizumab · Experimental
- Pembrolizumab + MK-4830 · Experimental
- Pembrolizumab + Belzutifan · Experimental
- Belzutifan + Lenvatinib · Experimental
- Pembrolizumab + Lenvatinib · Experimental
- Enrollment
- 263
- Primary outcomes
- Safety Lead-in Phase: Number of participants who experience one or more dose-limiting toxicities (DLTs)
- Safety Lead-in Phase: Number of participants who experience one or more adverse events (AEs)
- Safety Lead-in Phase: Number of participants who discontinue study treatment due to an AE
- Efficacy Phase: Number of participants who experienced DLTs
- Efficacy Phase: Number of participants who experience one or more AEs
- Efficacy Phase: Number of participants who discontinue study treatment due to an AE
- Efficacy Phase: Objective response rate (ORR)
- Sponsor
- Merck Sharp & Dohme LLC
- Start
- Dec 17, 2020
- Primary completion
- Jul 23, 2026
- Results posted
- No
- Registry record
- NCT04626518 · updated Sep 25, 2026